Revive Therapeutics (RVV) AI Stock Analysis

• Market Cap: C$6.28M
• Dividend Yield: N/A
• Average Volume (3M): 277.68K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.17
• Revenue Growth: N/A
• EPS Growth: -4.84%
• Country: CA
• Employees: 2
• Sector: Healthcare
• Sector Strength: 65
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 418,564,270
• 10 Day Avg. Volume: 479,046
• 30 Day Avg. Volume: 277,682
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -4.80
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Revive Therapeutics is currently challenged by significant financial issues, particularly the lack of revenue and ongoing losses. However, its technical indicators show strong momentum, albeit with overbought signals. The strategic initiatives in acquiring new programs and advancing research provide potential future growth opportunities but carry inherent risks. Overall, the stock is risky given its current financial performance, but corporate actions may offer upside potential if successful.

Revive Therapeutics Business Overview & Revenue Model

Company Description

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has research collaboration agreements with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; North Carolina State University for the development of a biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform; the University of California, San Francisco to explore the use of Bucillamine as a treatment for severe COVID-19; University of Health Sciences Antigua for the clinical research of psychedelics; and PharmaTher for the development of psilocybin microneedle patch. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

How the Company Makes Money

Revive Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company engages in strategic partnerships and licensing agreements for its drug candidates, particularly in areas such as rare disorders and infectious diseases. Revenue streams may include upfront payments, milestone payments, and royalties from successful commercialization efforts. Additionally, Revive Therapeutics may receive funding from grants and research collaborations with academic and industry partners.

Revive Therapeutics Financial Statement Overview

Summary

Revive Therapeutics is facing financial challenges with no revenue and continuous operating losses. The reliance on equity financing and declining cash reserves reflect a need for strategic shifts to improve revenue and cash flow.

Income Statement

Revive Therapeutics has shown no revenue generation over the last several years, resulting in consistently negative gross profit. The negative EBIT and EBITDA margins indicate significant operating losses. The company reported substantial net losses across the periods reviewed, indicating ongoing financial challenges and the need for revenue growth to improve profitability.

Balance Sheet

The balance sheet reflects a relatively stable equity base with no current debt obligations, which is a positive indicator of financial health. However, the shrinking of total assets over time and the consistent reduction in stockholders' equity suggest a potential depletion of resources. The company has maintained an equity ratio suggesting reliance on equity financing, but the reduction in cash reserves is concerning.

Cash Flow

The cash flow statements reveal negative operating cash flows, indicating cash outflows from operations, which is unsustainable long-term without revenue generation. The company has managed to secure financing to cover its operational deficits, but the lack of free cash flow growth is a significant concern. The absence of positive operating cash flow underscores the need for strategic changes to improve cash generation.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-164.00	-328.00	-434.00	-578.00	-775.00	-28.27K
	EBIT
-2.09M	-3.29M	-5.41M	-17.72M	-18.50M	-4.84M
	EBITDA
-5.29M	-5.60M	-5.52M	-17.74M	-18.57M	-5.26M
	Net Income Common Stockholders
-5.29M	-5.62M	-6.32M	-17.83M	-20.20M	-4.27M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
55.41K	823.07K	2.09M	3.92M	16.60M	1.48M
	Total Assets
9.72M	10.64M	14.25M	17.07M	29.81M	8.26M
	Total Debt
0.00	25.22K	219.69K	327.73K	415.84K	465.85K
	Net Debt
-55.41K	-797.85K	-1.87M	-3.59M	-16.18M	-915.63K
	Total Liabilities
3.32M	3.40M	3.60M	4.46M	999.68K	831.55K
	Stockholders Equity
6.39M	7.23M	10.65M	12.60M	28.81M	7.43M
Cash Flow		Free Cash Flow
-2.60M	-3.29M	-6.03M	-13.06M	-11.31M	-2.52M
	Operating Cash Flow
-2.60M	-3.29M	-6.03M	-13.06M	-8.31M	-2.52M
	Investing Cash Flow
-30.00K	0.00	0.00	0.00	-2.72M	142.24K
	Financing Cash Flow
1.98M	1.98M	4.20M	376.35K	26.24M	3.28M

Revive Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RVV, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and above the 200-day MA of 0.01, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 99.19 is Negative, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:RVV.

Revive Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RVV	49 Neutral	C$6.28M	―	-66.49%	―	―	-4.84%
Sector *	48 Neutral	$6.86B	1.11	-51.04%	2.47%	16.66%	1.53%

Revive Therapeutics Corporate Events

Revive Therapeutics Aligns with Shareholders in Annual Meeting Decisions

Revive Therapeutics announced the results of its annual shareholder meeting, where key decisions included the election of board members and the appointment of Horizon Assurance LLP as the company’s auditor. The board also decided against amending the company’s articles to consolidate common shares, reflecting shareholder feedback. This meeting underscores Revive’s commitment to aligning with shareholder interests and maintaining strategic focus on its therapeutic development programs.

Revive Therapeutics to Acquire DiagnaMed’s Molecular Hydrogen Program for Neurological Treatments

Revive Therapeutics has announced a non-binding letter of intent to acquire DiagnaMed’s molecular hydrogen program, which includes intellectual property for potential treatments of neurological and mental health disorders. This acquisition, expected to close by March 31, 2025, aims to advance the clinical development of molecular hydrogen, particularly for ALS, a disease with limited treatment options. The FDA’s orphan drug designation for molecular hydrogen in ALS provides hope for affected patients, and Revive plans to collaborate with researchers and advocacy groups to expedite its development. Additionally, Revive has secured a $65,000 loan to assist with its current working capital needs.

Revive Therapeutics Advances Bucillamine Research for Nerve Agents and Long COVID

Revive Therapeutics announced updates on its focus on Bucillamine for nerve agent exposure and long COVID treatment. Collaborating with Defence R&D Canada, the company is exploring Bucillamine’s potential as a treatment for nerve agent exposure, while also investigating its efficacy against long COVID symptoms, leveraging promising early results from past studies. If successful, this could lead to further studies and potential FDA and Health Canada approvals, impacting stakeholders by potentially expanding available treatments for these serious health concerns.

Revive Therapeutics Advances Research on Bucillamine for Nerve Agent Exposure

Revive Therapeutics announced an update on its research study evaluating Bucillamine for nerve agent exposure in collaboration with Defence R&D Canada. This study’s promising results may lead to further development and approval processes for using Bucillamine in treating nerve agent and organophosphate pesticide poisoning, with potential applications for traumatic brain injuries and viral infections.